Tomoya Oishi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tomoya Oishi has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Kazuhiko Kurozumi
Department of Neurosurgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
4 shared publications - Shinichiro Koizumi
Department of Neurosurgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
2 shared publications Tomohiro Yamasaki
Department of Neurosurgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
2 shared publications- Balveen Kaur
Department of Neurosurgery and Interdisciplinary Oncology, Louisiana State University Health Science Center-Louisiana, New Orleans, USA
1 shared publication Chika Sato
Department of Rehabilitation, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
1 shared publication- Dang Ngoc Phuong Dung
Department of Neurosurgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
1 shared publication
Latest Publications
- 14 August 2026
- Published by Springer Nature in Cancer Gene Therapy
- p. 1-12
Potential for enhanced oncolytic HSV-1 therapy via SHED as a vehicle against malignant gliomas
Malignant gliomas are common primary brain tumors. Glioblastoma carries a poor prognosis, with median survival of less than 2 years. Given the urgent need for novel therapies, oncolytic virus (OV) therapy has developed rapidly. However, challenges remain with effective OV delivery to tumor sites and efficient infection of tumor cells. This study investigated the use of stem cells from human exfoliated deciduous teeth (SHED) as a potential vehicle for oncolytic herpes simplex virus-1 therapy (SHED-OV) to enhance treatment efficacy. SHED-OV showed a greater reduction in tumor cell viability in vitro than direct OV infection. Migration assays revealed that SHED-OV actively migrated toward glioma cell-conditioned medium, demonstrating their tumor-homing ability. In vivo experiments demonstrated significantly prolonged survival in both the glioma cell/SHED-OV co-implantation group and the OV-infected glioma cell group compared with controls. In a glioma stem cell model, both SHED-OV and OV alone significantly improved survival compared with controls, with SHED-OV achieving anti-tumor effects comparable to those of direct OV administration and complete tumor regression in a subset of mice. SHED-OV also exhibited tumor-homing ability. These results suggest that SHED could serve as an effective vehicle for OV delivery, potentially improving tumor infection and therapeutic efficacy.
- 14 August 2026
- Published by Springer Nature in Cancer Gene Therapy
- p. 1-12
Potential for enhanced oncolytic HSV-1 therapy via SHED as a vehicle against malignant gliomas
Malignant gliomas are common primary brain tumors. Glioblastoma carries a poor prognosis, with median survival of less than 2 years. Given the urgent need for novel therapies, oncolytic virus (OV) therapy has developed rapidly. However, challenges remain with effective OV delivery to tumor sites and efficient infection of tumor cells. This study investigated the use of stem cells from human exfoliated deciduous teeth (SHED) as a potential vehicle for oncolytic herpes simplex virus-1 therapy (SHED-OV) to enhance treatment efficacy. SHED-OV showed a greater reduction in tumor cell viability in vitro than direct OV infection. Migration assays revealed that SHED-OV actively migrated toward glioma cell-conditioned medium, demonstrating their tumor-homing ability. In vivo experiments demonstrated significantly prolonged survival in both the glioma cell/SHED-OV co-implantation group and the OV-infected glioma cell group compared with controls. In a glioma stem cell model, both SHED-OV and OV alone significantly improved survival compared with controls, with SHED-OV achieving anti-tumor effects comparable to those of direct OV administration and complete tumor regression in a subset of mice. SHED-OV also exhibited tumor-homing ability. These results suggest that SHED could serve as an effective vehicle for OV delivery, potentially improving tumor infection and therapeutic efficacy.
- Open Access
- 27 March 2026
- Published by Elsevier in World Neurosurgery
- Vol. 210, 124940
Postoperative Writing Impairment in Glioma Patients Undergoing Awake Craniotomy
- 27 March 2026
- Published by Elsevier in World Neurosurgery
- Vol. 210, 124940
Open AccessPostoperative Writing Impairment in Glioma Patients Undergoing Awake Craniotomy
- Open Access
- 1 October 2025
- Published by Elsevier in Radiology Case Reports
- Vol. 20 (12) , 6257-6261
Sigmoid sinus dural arteriovenous fistula presenting with pulsatile tinnitus in the postpartum period: A case report
- 1 October 2025
- Published by Elsevier in Radiology Case Reports
- Vol. 20 (12) , 6257-6261
Open AccessSigmoid sinus dural arteriovenous fistula presenting with pulsatile tinnitus in the postpartum period: A case report
- 23 April 2024
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 31 (9) , 1306-1314
Mesenchymal stem cells as therapeutic vehicles for glioma
Glioma is a disease with a poor prognosis despite the availability of multimodality treatments, and the development of novel therapies is urgently needed. Challenges in glioma treatment include the difficulty for drugs to cross the blood–brain barrier when administered systemically and poor drug diffusion when administered locally. Mesenchymal stem cells exhibit advantages for glioma therapy because of their ability to pass through the blood–brain barrier and migrate to tumor cells and their tolerance to the immune system. Therefore, mesenchymal stem cells have been explored as vehicles for various therapeutic agents for glioma treatment. Mesenchymal stem cells loaded with chemotherapeutic drugs show improved penetration and tumor accumulation. For gene therapy, mesenchymal stem cells can be used as vehicles for suicide genes, the so-called gene-directed enzyme prodrug therapy. Mesenchymal stem cell-based oncolytic viral therapies have been attempted in recent years to enhance the efficacy of infection against the tumor, viral replication, and distribution of viral particles. Many uncertainties remain regarding the function and behavior of mesenchymal stem cells in gliomas. However, strategies to increase mesenchymal stem cell migration to gliomas may improve the delivery of therapeutic agents and enhance their anti-tumor effects, representing promising potential for patient treatment.
- 23 April 2024
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 31 (9) , 1306-1314
Mesenchymal stem cells as therapeutic vehicles for glioma
Glioma is a disease with a poor prognosis despite the availability of multimodality treatments, and the development of novel therapies is urgently needed. Challenges in glioma treatment include the difficulty for drugs to cross the blood–brain barrier when administered systemically and poor drug diffusion when administered locally. Mesenchymal stem cells exhibit advantages for glioma therapy because of their ability to pass through the blood–brain barrier and migrate to tumor cells and their tolerance to the immune system. Therefore, mesenchymal stem cells have been explored as vehicles for various therapeutic agents for glioma treatment. Mesenchymal stem cells loaded with chemotherapeutic drugs show improved penetration and tumor accumulation. For gene therapy, mesenchymal stem cells can be used as vehicles for suicide genes, the so-called gene-directed enzyme prodrug therapy. Mesenchymal stem cell-based oncolytic viral therapies have been attempted in recent years to enhance the efficacy of infection against the tumor, viral replication, and distribution of viral particles. Many uncertainties remain regarding the function and behavior of mesenchymal stem cells in gliomas. However, strategies to increase mesenchymal stem cell migration to gliomas may improve the delivery of therapeutic agents and enhance their anti-tumor effects, representing promising potential for patient treatment.